



Press release

## FluoGuide appoints Henrik Moltke as Chief Financial Officer

**Copenhagen, 21 September 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) today announces the appointment of Henrik Moltke as Chief Financial Officer (CFO). Henrik Moltke will begin his employment in December 2020.**

FluoGuide is strengthen its partnering, financing and other commercial activities to take full advantages of the upcoming results of the ongoing clinical phase I/II trial, testing FG001 in guiding surgical treatment of high grade glioma (including glioblastoma).

Henrik Moltke, who will be part of FluoGuide’s management team, brings more than 30 years of experience from life sciences and health care sectors, where he has held roles such as CFO and Senior Vice President. The primary focus in his previous career has been in venture financing, including IPOs as well as follow on capital increases in the public markets, investor relations, business development, finance planning and strategic development. Henrik Moltke will begin his employment in December 2020.

*“We look very much forward to welcoming Henrik to our team. With a CFO, and one with Henriks calibre, we will be able to accelerate our commercial activities hand-in-hand with developing FG001 towards broad clinical use to the benefit of patients with aggressive brain cancer”,* says Morten Albrechtsen, CEO of FluoGuide A/S.

*“I look forward to joining FluoGuide’s team and contribute to maturing the company to become a leader in guided oncology surgery”,* says Henrik Moltke.

### For further information:

Morten Albrechtsen, CEO  
Phone: +45 24 25 62 66  
E-mail: [ma@fluoguide.com](mailto:ma@fluoguide.com)

### About FluoGuide

FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is undertaking a proof-of-concept clinical trial (phase I/II) to demonstrate the effect of FG001 in patients with glioblastoma.



*This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.*